非典型脑膜瘤进展的组织病理学危险因素:评估核分裂计数与Ki-67影响及临床价值的回顾性队列研究
该单中心回顾性队列纳入2001至2020年手术治疗的240例非典型脑膜瘤患者,用Youden指数确定核分裂计数与Ki-67截断值,分析进展危险因素。结果显示32.5%患者出现进展,中位进展时间25.2个月;核分裂计数≥6与进展显著相关,即使在全切除患者中亦如此,放疗改善次全切除患者无进展生存。
要点
- 核分裂计数≥6是非典型脑膜瘤进展的独立危险因素。
- 全切除和辅助放疗可能降低非典型脑膜瘤进展风险。
- 次全切除患者应接受辅助放疗,全切除伴高核分裂计数者需更密切随访。
核心结论
- 全切除和辅助放疗可能降低非典型脑膜瘤进展。
- 核分裂计数≥6显著增加进展风险,即使在全切除患者中亦如此。
- 次全切除患者应考虑辅助放疗,全切除患者若核分裂计数高则需更密切随访或考虑放疗。
研究设计与样本
- 单中心回顾性队列研究,纳入2001至2020年手术治疗的240例连续非典型脑膜瘤患者。
- 采用Youden指数确定核分裂计数与Ki-67截断值,用病因特异性Cox比例风险模型分析进展危险因素。
- 用累积发生率函数估计无进展生存,用Gray检验比较。
主要发现
- 32.5%患者出现非典型脑膜瘤进展,中位进展时间25.2个月,中位随访42.3个月。
- 未确定有临床意义的Ki-67截断值,核分裂计数≥6与进展显著相关。
- 多变量分析中,年龄、全切除、核分裂计数≥6、脑侵犯、片状生长和辅助放疗与进展相关。
- 辅助放疗改善次全切除组的无进展生存,但未改善全切除组。
- 全切除患者中核分裂计数≥6者结局更差。
关键数值与推荐
- 核分裂计数≥6为截断值,与进展显著相关。
- Ki-67截断值未确定有临床意义。
- 次全切除患者应考虑辅助放疗。
- 全切除患者核分裂计数高时需更密切随访或考虑放疗。
临床怎么用
- 对非典型脑膜瘤术后病理应关注核分裂计数,≥6提示进展风险高。
- 次全切除的非典型脑膜瘤患者建议辅助放疗。
- 全切除且核分裂计数≥6的患者应加强随访,可考虑辅助放疗。
- Ki-67截断值在此研究中未显示明确临床价值。
局限性
- 单中心回顾性设计。
- Ki-67截断值未确定有临床意义。
- 中位随访42.3个月,可能不足以评估长期进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Given the heterogeneity of atypical meningioma (AM) and potential interobserver variability in WHO grade assignment among pathologists, there is a need for more objective criteria to improve risk stratification. This study examined conventional and novel risk factors for AM progression, focusing on mitotic count (MC) and Ki-67, and explored their clinical relevance. METHODS: This retrospective cohort study included 240 consecutive patients with AM surgically treated at a single tertiary institution between 2001 and 2020. The cut-off values for MC and Ki-67 were determined using the Youden index. Risk factors for progression were analyzed using cause-specific Cox proportional hazards models. Progression-free survival (PFS) was estimated using cumulative incidence function (CIF) and compared using the Gray's test. RESULTS: AM progression occurred in 32.5% of patients with a median time to progression of 25.2 months. The median follow-up was 42.3 months. While a clinically meaningful Ki-67 cut-off was not identified, MC ≥ 6 was significantly associated with AM progression. On multivariate analysis, age, gross total resection (GTR), MC ≥ 6, brain invasion, sheeting, and adjuvant radiotherapy (RTx) were associated with progression. RTx improved PFS in the subtotal resection (STR) group but not in the GTR group. Among GTR patients, those with MC ≥ 6 had worse outcomes. CONCLUSION: GTR and RTx may reduce the progression of AM. MC ≥ 6 significantly increases the risk of progression, even in GTR patients. RTx should be considered for all STR patients A more vigilant follow-up or consideration of RTx is warranted in GTR patients when a high MC is identified.
引用
- Byun YH, Han M, Nam SM, et al. Histopathologic risk factors for progression of atypical meningioma: a retrospective cohort study evaluating the impact and clinical value of mitotic count and Ki-67. Acta Neurochir (Wien). 2025. PMID: 41324743. doi:10.1007/s00701-025-06711-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。